Rong Shao to Antineoplastic Agents
This is a "connection" page, showing publications Rong Shao has written about Antineoplastic Agents.
Connection Strength
0.364
-
Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011 May; 10(5):742-51.
Score: 0.252
-
Zhang H, Zhang S, He H, Zhao W, Chen J, Shao RG. GAP161 targets and downregulates G3BP to suppress cell growth and potentiate cisplaitin-mediated cytotoxicity to colon carcinoma HCT116 cells. Cancer Sci. 2012 Oct; 103(10):1848-56.
Score: 0.069
-
Sha MQ, Zhao XL, Li L, Li LH, Li Y, Dong TG, Niu WX, Jia LJ, Shao RG, Zhen YS, Wang Z. EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells. Cell Death Dis. 2016 11 24; 7(11):e2486.
Score: 0.023
-
Sun YR, Zhang SH, Shao RG, He HW. [The synergistic effect of lidamycin and rituximab on human B cell lymphoma]. Yao Xue Xue Bao. 2014 Feb; 49(2):198-203.
Score: 0.019